United States

Back to map

Showing 261-270 of 325 grants

Title Institution Researcher Program Duration Total Award Amount
Discovering early diagnostic markers of cardiovascular disease risk with lipidomics in a 30-year longitudinal prospective type 1 diabetes cohort University of Wisconsin-Madison (Board of Regents University of Wisconsin System) Judith Simcox Improving Lives 01-November-2022 to 04-May-2026 $799.988,63
Development of a new nanotechnology for immune-tolerizing therapy against T1D EVOQ Therapeutics, Inc. Vishalakshi Krishnan Cures 01-September-2022 to 28-February-2026 $1.110.000,00
Assessment of Beta Cell Small Extracellular Vesicles in the Pathogenesis of Type 1 Diabetes Mayo Clinic Naureen Javeed Cures 01-September-2022 to 31-August-2025 $400.000,00
Using genetics to better diagnose and treat adult-onset T1D in multi-ethnic US population Geisinger Clinic David Carey Cures 01-November-2022 to 30-September-2026 $1.469.640,10
Bioactive Granular Hydrogels for Islet Delivery Regents of the University of Michigan Maria Coronel Cures 01-September-2022 to 31-August-2025 $400.000,00
A Multi-task Learning Framework for Developing Genetic Risk Score (GRS) Models of T1D for Multi-Ethnic Population University of Washington Shuai Huang Cures 01-August-2022 to 31-August-2025 $300.081,37
Improving prediction of T1D risk by establishing a self-administered CGM-based technology and whole genome-based polygenic risk scores in diverse populations Rector & Visitors of the University of Virginia Leon Farhy Cures 01-August-2022 to 31-July-2025 $599.999,66
Phenotyping RElatives of persons with Diabetes with CGM and Tests of beta-cell function and health (PREDICT): an integrated longitudinal assessment of deep metabolic phenotyping and CGM metrics in youth at risk for T1D Yale University Alfonso Galderisi Cures 01-February-2023 to 31-January-2026 $747.380,88
PREdictors for DiabetIC Ketoacidosis at Diagnosis of Type 1 Diabetes (The PREDICT study) Rutgers, The State University of New Jersey Chintan Dave Cures 01-August-2022 to 31-July-2025 $695.404,04
Novel Combination Regimen Therapy to Modulate Pro- and Anti-inflammatory Lipid Signaling to Counter T1D The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham Sasanka Ramanadham Cures 01-July-2022 to 30-June-2025 $594.999,97